Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

about

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q49999453

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma.

@en

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma.

@nl

type

Item

label

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma.

@en

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma.

@nl

prefLabel

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma.

@en

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma.

@nl

P1476

Phase IIa study of the CD19 an ...... B-cell non-Hodgkin's lymphoma

@en

P2093

A Goy

http://www.w3.org/2001/XMLSchema#string

C Buske

http://www.w3.org/2001/XMLSchema#string

G Gaidano

http://www.w3.org/2001/XMLSchema#string

K A Blum

http://www.w3.org/2001/XMLSchema#string

K Maddocks

http://www.w3.org/2001/XMLSchema#string

M Dirnberger-Hertweck

http://www.w3.org/2001/XMLSchema#string

M Winderlich

http://www.w3.org/2001/XMLSchema#string

R Korolkiewicz

http://www.w3.org/2001/XMLSchema#string

S Ambarkhane

http://www.w3.org/2001/XMLSchema#string

T Robak

http://www.w3.org/2001/XMLSchema#string

P2860

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival.

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

P304

1266-1272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDY056

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mariano Provencio

Pier Luigi Zinzani

Wojciech Jurczak

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29444231

http://www.w3.org/2001/XMLSchema#string

P932

5961010

http://www.w3.org/2001/XMLSchema#string